Syndrome | Prevalence (%) | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | LR+ (95% CI) | LR- (95% CI) |
---|---|---|---|---|---|---|---|
Functional loss | 14.0 | 91.7 (61.5–99.8) | 95.8 (88.1–99.1) | 78.6 (49.2–95.3) | 98.6 (92.2–100.0) | 21.7 (7.1–66.5) | 0.1 (0.0–0.6) |
Cognitive impairment | 29.8 | 64.0 (42.5–82.0) | 67.2 (53.7–79.0) | 45.7 (28.8–63.4) | 81.3 (67.4–91.1) | 2.0 (1.2–3.1) | 0.5 (0.3–0.9) |
Mood impairment | 37.7 | 65.6 (46.8–81.4) | 64.2 (49.8–76.9) | 52.5 (36.1–68.5) | 75.6 (60.5–87.1) | 1.8 (1.2–2.8) | 0.5 (0.3–0.9) |
Urinary incontinence | 43.5 | 76.5 (58.8–89.3) | 85.4 (72.2–93.9) | 78.8 (61.1–91.0) | 83.7 (70.3–92.7) | 5.2 (2.6–10.7) | 0.3 (0.1–0.5) |
Gait and balance | 34.9 | 67.9 (47.6–84.1) | 73.6 (59.7–84.7) | 57.6 (39.2–74.5) | 81.3 (67.4–91.1) | 2.6 (1.5–4.3) | 0.4 (0.2–0.8) |
Visual impairment | 71.1 | 81.4 (69.1–90.3) | 45.8 (25.6–67.2) | 78.7 (66.3–88.1) | 50.0 (28.2–71.8) | 1.5 (1.0–2.2) | 0.4 (0.2–0.8) |
Hearing impairment | 47.6 | 82.1 (66.5–92.5) | 86.0 (72.1–94.7) | 84.2 (68.7–94.0) | 84.1 (69.9–93.4) | 5.9 (2.8–12.5) | 0.2 (0.1–0.4) |
Undernutrition | 28.9 | 25.0 (9.8–46.7) | 87.7 (76.3–94.9) | 46.2 (19.1–74.9) | 73.5 (61.4–83.5) | 2.0 (0.8–5.4) | 0.9 (0.7–7.8) |
Osteoporosis | 47.5 | 77.8 (60.8–89.9) | 65.9 (49.4–79.9) | 66.7 (50.5–80.4) | 77.1 (59.9–89.6) | 2.3 (1.4–3.6) | 0.3 (0.2–0.6) |